| Name | Title | Contact Details |
|---|---|---|
Douglas Castor |
Vice President - Talent Acquisition - Strategic Sourcing and Employment Branding | Profile |
Douglas Castor |
Vice President of Talent Acquisition and Employment Branding | Profile |
Tabitha Fahy |
Director Learning and Development | Profile |
Cheryl Doggett |
Vice President and Chief Talent Officer | Profile |
We believe affordable, convenient vision prescriptions are a good thing. We started Opternative to provide a safe, online option for vision testing. It`s a way to get prescriptions between eye exams. Eyes stay healthy. People can see clearly. It`s a win-win.
Chem Rx Corporation, formerly Paramount Acquisition Corp., provides institutional pharmacy services to skilled nursing facilities, assisted living facilities, residential living facilities, addiction treatment centers and other long-term healthcare
Since 1945, we`ve taken our role as an Idaho-based health insurance company to heart. While the health insurance marketplace has experienced lots of change in recent years, we haven`t. As a not-for-profit, we`re mission-driven to help connect Idahoans to quality healthcare that is affordable and build strong networks and services with our customers in mind. With an annual economic impact of $456 million (in 2016), we lead the state and industry in addressing the cost of healthcare and creating transformative customer experiences with information, tools and services. Ultimately, we aim to create a brighter future for all of us. All we need are customer-centric leaders like you.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
Diamond Healthcare Corporation is the national leader in the planning, development and operation of high quality Behavioral Health Services in partnership with healthcare organizations. Diamond`s client relationships span a diverse geographic and demographic range — from rural critical access hospitals to urban academic medical centers, from sole community hospitals to multi-hospital health systems, including faith-based healthcare organizations, not-for-profit systems and for-profit hospital companies. Diamond offers a comprehensive range of healthcare services.